Study Title and Description
Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.
Key Questions Addressed
|1||How do different methods for detection of toxigenic C. difficile to assist with diagnosis of CDI compare in their sensitivity, specificity, and predictive values? a. Overall? b. Do performance measures vary with sample characteristics? c. Does testing strategy impact patient health or health system outcomes?|
|2||What are effective prevention strategies? a. What is the effectiveness of current prevention strategies? b. What are the harms associated with prevention strategies? c. How sustainable are prevention practices in health care (outpatient, hospital inpatient, extended care) and community settings?|
|3||What is the comparative effectiveness and harms of different antibiotic treatments? a. Does effectiveness vary by disease severity?|
|4||What are the effectiveness and harms of other interventions? a. Overall b. In patients with relapse/recurrent CDI.|
Primary Publication Information
|Title||Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.|
|Author||McFarland LV., Surawicz CM., Greenberg RN., Elmer GW., Moyer KA., Melcher SA., Bowen KE., Cox JL.|
|Country||Department of Medicinal Chemistry, University of Washington, Seattle.|
Pubmed ID: 7872284
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Detection, prevention, treatments, and efficacy and harms of interventions for C. difficile
Results & Comparisons
No Results found.